Bentley and Dong Sung Enter Into Licensing Agreement

Bentley Pharmaceuticals, a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that it has entered into an agreement with Dong Sung Pharm. for the development of an intranasal spray formulation of insulin for the South Korean market and possibly additional territories. The agreement is Bentley's first to develop and license its intranasal spray formulation of insulin.

Yahoo News (http://biz.yahoo.com/bw/050425/255259.html?.v=1)